Dossier
malignancy rates
Coverage of malignancy rates in the Nexus archive.
- Abivax stock surges as new trial data ease cancer fears over bowel disease drug
Abivax stock surged following new Phase 3 trial data indicating malignancy rates among ulcerative colitis patients align with typical expectations, easing concerns about cancer risks linked to the bowel disease drug.